Literature DB >> 22177843

Limited efficacy of uterine artery embolization for cervical leiomyomas.

Man Deuk Kim1, Myungsu Lee, Dae Chul Jung, Sung Il Park, Mu Sook Lee, Jong Yun Won, Do Yun Lee, Kwang Hun Lee.   

Abstract

PURPOSE: To explore the effectiveness of uterine artery embolization (UAE) in treating symptomatic fibroids in the uterine cervix.
MATERIALS AND METHODS: Among 537 patients who underwent UAE, 10 who had fibroids located in the cervix were retrospectively analyzed. The mean diameter of the fibroids was 6.0 cm. Seven of the 10 patients presented a total of 10 fibroids in the uterine body or fundus simultaneously. Fibroids of the cervix and fibroids in the body or fundus were compared in terms of the effects of UAE on the treatment thereof and vascularity on angiographic findings. Cervical leiomyomas were classified into three grades based on the vascularity seen on aortography, from grade I, indicating poor vascularity, to grade III, indicating hypervascularity. Necrosis of fibroids was assessed by magnetic resonance imaging 3 months after UAE.
RESULTS: Complete necrosis of leiomyomas in the uterine cervix was seen in only two of the 10 patients (20%), whereas all fibroids in the uterine body or fundus were completely infarcted (P < .05). Partial necrosis (PN) of the fibroid with a thin viable rim was seen in two patients, whereas PN with a thick rim was seen in four and no necrosis was seen in two. Grade I (ie, poor) vascularity was noted in five of nine patients (55.6%) with cervical fibroids larger than 3 cm.
CONCLUSIONS: Poor vascularity was a frequent finding among cervical leiomyomas, and the outcomes of UAE for cervical leiomyomas were disappointing, indicating a need for caution in selecting and counseling patients for this treatment.
Copyright © 2012 SIR. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22177843     DOI: 10.1016/j.jvir.2011.10.020

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

1.  Structured vs narrative reporting of pelvic MRI for fibroids: clarity and impact on treatment planning.

Authors:  Andrea Franconeri; Jieming Fang; Benjamin Carney; Almamoon Justaniah; Laura Miller; Hye-Chun Hur; Louise P King; Roa Alammari; Salomao Faintuch; Koenraad J Mortele; Olga R Brook
Journal:  Eur Radiol       Date:  2017-12-15       Impact factor: 5.315

Review 2.  Preprocedural MRI and MRA in planning fibroid embolization.

Authors:  Cristina Maciel; Yen Zhi Tang; Anju Sahdev; António Miguel Madureira; Paulo Vilares Morgado
Journal:  Diagn Interv Radiol       Date:  2017 Mar-Apr       Impact factor: 2.630

3.  Low vascularity predicts favourable outcomes in leiomyoma patients treated with uterine artery embolization.

Authors:  Yixin Tang; Chunlin Chen; Hui Duan; Ben Ma; Ping Liu
Journal:  Eur Radiol       Date:  2016-01-27       Impact factor: 5.315

4.  European Society of Urogenital Radiology (ESUR) Guidelines: MR Imaging of Leiomyomas.

Authors:  Rahel A Kubik-Huch; Michael Weston; Stephanie Nougaret; Henrik Leonhardt; Isabelle Thomassin-Naggara; Mariana Horta; Teresa Margarida Cunha; Cristina Maciel; Andrea Rockall; Rosemarie Forstner
Journal:  Eur Radiol       Date:  2018-02-28       Impact factor: 5.315

5.  Impact of grayscale and Doppler ultrasound characteristics on reducing the size of tumors in the treatment of uterine fibroids by uterine artery embolization.

Authors:  Azim Motamedfar; Mohammad Momen Gharibvand; Said Tamiz
Journal:  Contemp Oncol (Pozn)       Date:  2019-04-05

Review 6.  Current Treatment Options for Cervical Leiomyomas: A Systematic Review of Literature.

Authors:  Federico Ferrari; Sara Forte; Gaetano Valenti; Laura Ardighieri; Fabio Barra; Valentina Esposito; Enrico Sartori; Franco Odicino
Journal:  Medicina (Kaunas)       Date:  2021-01-21       Impact factor: 2.430

7.  Uterine Artery Embolization for Leiomyomas and Adenomyosis: A Pictorial Essay Based on Our Experience from 1300 Cases.

Authors:  Man Deuk Kim
Journal:  Korean J Radiol       Date:  2019-10       Impact factor: 3.500

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.